Abciximab (Reopro):


Abciximab (Reopro): Glycoprotein IIb/IIIa inhibitor preventing platelet adhesion and aggregation.


Indications: Prevent thrombus formation peri-PTCA and poststent placement.

Administration guidelines

Administration guidelines

  1. Standard concentration: 9 mg/250 mL 0.9% sodium chloride.
  2. The IV tubing must have a filter on it (0.2- or 0.22-μm low-protein-binding filter) and no other medications should be piggybacked through this line.
  3. Loading dose (straight drug): 0.25 mg/kg administered 10 to 60 minutes prior to PCI. Withdraw through the 0.2- or 0.22-μm low-protein-binding filter the appropriate amount of abciximab for the patient's weight. Hypotension may occur with bolus dose.
  4. Maintenance at a rate of 0.125 μg/kg/min to a max of 10 μg/min (17 mL/h) for 12 hours. To prepare, withdraw 4.5 mL (9 mg) of abciximab through 0.2- or 0.22-μm low-protein-binding filter and inject into 250-mL bag of 0.9% sodium chloride.

Abciximab (Reopro): is a sample topic from the Clinical Anesthesia Procedures.

To view other topics, please or .

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. .